期刊
JOURNAL OF NEUROLOGY
卷 269, 期 4, 页码 1786-1801出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-021-10783-4
关键词
NMOSD; Neuromyelitis optica; NMO; Symptomatic; Neuropathic pain; Tonic spasms; Remyelination; Mesenchymal stem cells
资金
- Guthy-Jackson Charitable Foundation
Neuromyelitis optica spectrum disorders are autoimmune inflammatory conditions that primarily affect the optic nerves, spinal cord, and other areas, leading to recurrent attacks of visual, motor, and sensory dysfunction. While progress has been made in prevention and treatment, the residual disability per attack remains high. Treatment options for NMOSD are limited but can be inferred from therapies used in other diseases.
Neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune inflammatory conditions that primarily target the optic nerves, spinal cord, brainstem, and occasionally the cerebrum. NMOSD is characterized by recurrent attacks of visual, motor, and/or sensory dysfunction that often result in severe neurological deficits. In recent years, there has been a significant progress in relapse treatment and prevention but the residual disability per attack remains high. Although symptomatic and restorative research has been limited in NMOSD, some therapeutic approaches can be inferred from published case series and evidence from multiple sclerosis literature. In this review, we will discuss established and emerging therapeutic options for symptomatic treatment and restoration of function in NMOSD. We highlight NMOSD-specific considerations and identify potential areas for future research. The review covers pharmacologic, non-pharmacologic, and neuromodulatory approaches to neuropathic pain, tonic spasms, muscle tone abnormalities, sphincter dysfunction, motor and visual impairment, fatigue, sleep disorders, and neuropsychological symptoms. In addition, we briefly discuss remyelinating agents and mesenchymal stem cell transplantation in NMOSD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据